First subject dosed in Revolution Medicines’ Phase III NSCLC treatment trial
Revolution Medicines has dosed the first subject in the Phase III RASolve 301 trial with the RAS (ON) multi-selective inhibitor, …
Post
-
-
Podcast: AI and Supervised Machine Learning in Clinical Trials – Ep1
AI and supervised machine learning have considerable benefits for clinical trials. The first episode in this GlobalData-produced series by Zelta …
-
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
ADC Therapeutics has culled its clinical asset ADCT-602 while announcing more data on its flagship drug Zynlonta (loncastuximab tesirine-lpyl). Following the …
-
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
Pasithea Therapeutics has announced the start of a Phase I/Ib open-label trial of macrocyclic mitogen-activated protein kinase (MEK) inhibitor, PAS-004, …
-
Natural history research is powering more effective decision-making in oncology clinical trials
In the US alone, over 7,000 different rare diseases affect more than 30 million people[i]. Many of these conditions are …
-
Nuvig Therapeutics begins dosing in trial of NVG-2089 for CIDP
Nuvig Therapeutics has dosed the first subject in its multi-centre Phase II INVGOR trial of recombinant human immunoglobulin G1-crystallisable fragment …
-
Examining shifts in clinical trial outsourcing
As clinical trials grow increasingly complex and globalised, industry leaders continue to reassess how outsourcing models can drive efficiency and …
-
Childhood trauma and depressive predominance polarity in bipolar disorder
People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive episodes than manic …
-
BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug
US-based biopharmaceutical company BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to …
-
How to manage the complexities of synthetic API production in 30 steps
A synthetic active pharmaceutical ingredient (API) can offer a crucial option for drug manufacturing. Yet there can be many complexities …
-
GSK to spend $2bn on Phase III liver disease drug acquisition
Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire …
-
Roche reports final overall survival outcomes from breast cancer treatment trial
Swiss pharmaceutical company Roche has reported final overall survival outcomes from a long-term Phase III trial of Perjeta (pertuzumab) with …
-
GSK and iTeos drop anti-TIGIT drug following trial failure
GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a …
-
Connect Biopharma begins Phase II trial of drug for acute exacerbations in asthma
US-based biopharmaceutical company Connect Biopharma has started a Phase II trial to assess the efficacy and safety of rademikibart in …
-
In the Lyme light: New French study highlights potential underreporting
Lyme disease is a bacterial infection transmitted by bites from infected ticks commonly found in much of North America and …
